多西他赛联合奈达铂治疗老年晚期非小细胞肺癌的临床效果及对血清肿瘤标志物的影响

Clinical Effect of Docetaxel Combined with Nedaplatin on Elderly Patients with Advanced Non-small Cell Lung Cancer and Its Effect on Serum Tumor Markers

目的分析多西他赛分别联合顺铂、奈达铂治疗老年晚期非小细胞肺癌(NSCLC)的临床效果差异。方法回顾性分析贵溪市人民医院2019年1月到2021年12月收治的100例老年晚期NSCLC患者,按照不同治疗方法将其分为两组,对照组(n=50例)采取多西他赛联合顺铂治疗,观察组(n=50例)采取多西他赛联合奈达铂治疗,比较两组患者治疗效果。结果观察组治疗有效率明显高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清肿瘤标志物水平有所下降,且观察组低于对照组(P<0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。结论采取多西他赛联合奈达铂治疗老年晚期NSCLC患者效果显著,能有效改善血清肿瘤标志物,安全性较好。

Objective To analyze the clinical effect of docetaxel combined with nedaplatin in the treatment of elderly advanced non-small cell lung cancer(NSCLC)and its effect on serum tumor markers.Methods 100 elderly patients with advanced NSCLC treated in Guixi People's Hospital from January 2019 to December 2021 were retrospectively analyzed.They were divided into two groups according to different treatment methods.The control group(n=50 cases)was treated with cisplatin combined with docetaxel,and the observation group(n=50 cases)was treated with docetaxel combined with nedaplatin.Results The treatment rate in the observation group was significantly higher than that in the control group and the difference was statistically significant(P<0.05).After treatment,the levels of serum tumor markers in the two groups decreased,and the levels in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse effects between the two groups(P>0.05).Conclusion Docetaxel combined with nedaplatin is effective and safe in the treatment of elderly patients with advanced NSCLC.